Polar Power has completed Phase 1 of its strategic restructuring, reducing annual costs by about $1.03 million through personnel and facility savings. The company aims to strengthen operations and focus resources on converting a $4.5 million sales backlog into shipments and cash flow. Polar Power is targeting growth in telecom, defense, and distributed power markets, pursuing new opportunities including a 50-unit trial order from a major Southeast Asian telecom operator. Management plans further cost reductions and operational improvements to support scalable growth and enhanced financial discipline.
Polar Power's strategic restructuring is the subject here, providing context for readers. For those following the Industrials sector, of 135 priced US stocks tradable on Pluang, 46 rose and 88 fell today. Notable movers include SPCE at USD 2.35 with a 1-day change of -3.29% and 100% buy order activity, HONA at USD 162.74 down 3.18% with 100% sell order activity, and ADT at USD 6.81 up 3.18%. This data is as of Oct 20, 2026 03:01 WIB.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
